Last Updated : May 16, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Komboglyze | Saxagliptin + metformin | Diabetes Mellitus, type 2 | List with criteria/condition | Complete | ||
Kivexa | Abacavir/lamivudine | HIV infection | List in a similar manner to other drugs in class | Complete | ||
Kisqali | Ribociclib | Advanced or Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Kisqali | Ribociclib | HR+, HER2- advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Kisqali | Ribociclib with Fulvestrant | +Fulvestrant for HR+, HER2- advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Kineret | anakinra | Still's disease | Withdrawn | |||
Kimmtrak | tebentafusp | unresectable or metastatic uveal melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda and Lenvima | pembrolizumab and lenvatinib | Advanced endometrial cancer | Withdrawn | |||
Keytruda and Lenvima | pembrolizumab and lenvatinib | Advanced endometrial cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | Pembrolizumab | head and neck squamous cell carcinoma (HNSCC) | Reimburse with clinical criteria and/or conditions | Complete |